|
MedyTox is a biopharmaceutical company focused on the research, development, manufacturing, and sale of botulinum toxin type A drugs and hyaluronic acid fillers. Its primary product, Meditoxin (marketed as Neuronox, Siax, Botulift, Cunox, and Meditoxin), is a liquid botulinum toxin type A formulation developed using proprietary technology. The company also produces Innotox, a non-animal-derived liquid botulinum toxin type A drug, and Coretox, a newer formulation. Its medical device portfolio includes the Neuramis series of hyaluronic acid fillers and the lipolytic injection Newbju. MedyTox manufactures its products in South Korea and is developing a production facility in the United Arab Emirates. It sells its products domestically and internationally through distributors and joint ventures. The company has established partnerships with Allergan for clinical trials of a novel botulinum toxin formulation and with Dubai Science Park for facility construction. MedyTox was founded in 2000 and is part of a group that includes subsidiaries such as NewmeCo, Potentfill, Neuraderm, and Kanui. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage medytox.com |
| Sector Healthcare | IR page medytox.com | |
|
Tags
botulinum toxin, hyaluronic acid fillers, aesthetic medicine, neurotoxin, lipolytic injections, biopharmaceuticals, medical devices, Meditoxin, Neuronox, Siax, Botulift, Cunox, Innotox, Coretox, Neuramis, Newbju, NewmeCo, Potentfill, Neuraderm, Kanui, MedyTox Academy, MedyTox Business Center, MedyTox Venture Investment
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 516.427B |
| Market cap (USD) | $ 380.081M |
| P/E | 31.14 |
| PEG | — |
| P/BV | 1.38 |
| P/S | 2.06 |
| P/OCF | 7.55 |
| P/FCF | 9.49 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 3.6% |
| ROI | 3.7% |
| ROIC | 3.8% |
| Profit margin | 6.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Earnings growth 3y (net profit CAGR) | -23.5% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 18.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 247.29B | 228.622B | 221.121B | 195.096B | 184.87B | 140.828B | 205.9B | 205.445B | 181.239B | 133.256B | 88.505B | 75.892B | 39.141B |
| Net profit | 16.594B | 16.955B | 9.755B | 37.01B | 94.154B | -29.577B | 26.206B | 69.964B | 73.279B | 59.231B | 42.293B | 43.628B | 14.304B |
| Free cash flow | 45.749B | 27.83B | 5.862B | 16.304B | 2.452B | -13.217B | 12.682B | 46.572B | 21.641B | -82.398B | -7.731B | 88.744B | 43.077M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 31.4B | 56B | 67.4B | 61.3B | 42.9B | 44.2B | 53.9B | 68.9B | 58.4B | 59.4B |
| ↳ YoY growth | +66.3% | +78.6% | +20.3% | -9.0% | -30.0% | +3.2% | +21.8% | +27.9% | -15.3% | +1.8% |
| ↳ 5y CAGR | +43.8% | +33.6% | +17.9% | +7.1% | -0.8% | +0.5% | -1.0% | +6.7% | ||
| Borrowings, current (KRW) | 0.00 | — | — | — | — | — | 95.1B | 61.1B | 59.3B | 56.6B |
| Borrowings, non-current (KRW) | 61.8B | — | 0.00 | 0.00 | 28.2B | — | 20B | 0.00 | 20B | 18B |
| Bonds payable (KRW) | — | — | 0.00 | 0.00 | 28.2B | — | 32B | 0.00 | 0.00 | — |
| Lease liabilities (KRW) | — | — | — | — | — | — | 747M | 1.75B | 2.01B | 2.01B |
| Cash and deposits (KRW) | 15.8B | 26.4B | 19.2B | 20B | 44B | 71.8B | 20.7B | 33.2B | 46.2B | 48.9B |
| Intangible assets (KRW) | 19.3B | 28.4B | 21B | 22.3B | 18B | 11.8B | 26.5B | 54.2B | 72B | 77.6B |
| Right-of-use assets (KRW) | — | 0.00 | 0.00 | 761M | 873M | 884M | 743M | 1.72B | — | — |
| Net debt (borrowings + leases - cash) (KRW) | 46B | — | -19.2B | -20B | -15.8B | — | 95.2B | 29.6B | 35.1B | 27.7B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | 54.1B | 59.7B | 55.1B | 33.7B | 27.9B | 20B | 26.2B | 13.5B | 36.6B | 61.4B |
| Purchases of property, plant and equipment (KRW) | -136B | -38B | -8.5B | -21B | -41.1B | -17.5B | -9.9B | -7.66B | -8.73B | -15.7B |
| Purchases of intangible assets (KRW) | -8.17B | -8.67B | -3.52B | -2.64B | -3.16B | -3.83B | -15.2B | -29.8B | -10B | -18.6B |
| Change in receivables (cash effect) (KRW) | -10.4B | — | — | — | — | 17.2B | -13.9B | -30.6B | — | — |
| Change in inventories (cash effect) (KRW) | -1.17B | -4.48B | -9.84B | -6.99B | -12.3B | 1.4B | -19.5B | -8.91B | — | — |
| Change in payables (cash effect) (KRW) | 888M | — | — | — | — | -8B | 9.72B | 31.6B | — | — |
| Dividends paid (cash effect) (KRW) | -9.6B | -11.1B | -12.1B | -4.33B | -5.54B | 0.00 | -8.04B | -8.42B | -8.42B | -8.92B |
| Share buybacks (cash effect) (KRW) | -15.8B | -16.9B | 0.00 | -14.6B | -10.4B | -8.13B | -16.9B | -2.97B | -10.1B | -13.2B |
| Interest paid (cash effect) (KRW) | -911M | -2.03B | -1.87B | -2.05B | -2.58B | -3.63B | -2.41B | -3.8B | -4.33B | -1.41B |
| Income taxes paid (cash effect) (KRW) | -12B | -7.46B | -14.3B | -16.7B | 5.23B | -18B | -18.9B | -13.5B | -7.46B | -6.82B |
| Share-based compensation (KRW) | 459M | 5.23B | 4.82B | 1.87B | 4.12B | 3.9B | 1.81B | 1.83B | — | — |
| Operating cash flow before change in receivables (KRW) | 64.5B | — | — | — | — | 2.77B | 40.1B | 44.1B | — | — |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -90.6B | 13B | 43B | 10B | -16.4B | -1.38B | 1.1B | -23.9B | 17.8B | 27.2B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | 59.2B | 72.2B | 67.8B | 24.8B | -32B | 96.4B | 51B | 9.74B | 15.8B | 5.55B |
| Comprehensive income to owners (KRW) | 59.2B | 72.3B | 68B | 25.5B | -31.8B | 97.5B | 50.2B | 10.3B | 17B | 6.61B |
| Provision for credit losses (KRW) | -167M | 1.27B | 3.16B | 11.5B | 14.4B | 1.16B | 4.87B | 547M | — | — |
| Credit cost ratio (credit losses / average receivables) (%) | 0.7% | 2.9% | 5.1% | 17.9% | 27.7% | 2.7% | 9.9% | 0.9% | — | — |
| Reported | May 15, 2017 | Mar 30, 2020 | Aug 13, 2021 | Aug 14, 2020 | Aug 13, 2021 | Mar 21, 2024 | Mar 20, 2025 | Mar 20, 2025 | Mar 20, 2025 | Mar 19, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding MedyTox
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.